Cannabinoid receptor modulator

A compound represented by Formula (I′)

• wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R1 and R2 are independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted hydroxyl group, an optionally substituted mercapto group or an optionally substituted amino group, or R1 and R2 may be taken with the adjacent carbon atom to form an optionally substituted ring, R3′ is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted mercapto group or an optionally substituted amino group, R4′ is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heterocyclic group, Y is —CO—, —SO—, or —SO2—, R5 is a hydrogen atom or an optionally substituted hydrocarbon group, R6′ is an optionally substituted hydrocarbon group (provided that both of R1 and R2 are not a hydrogen atom, R6′ has no benzene ring), an optionally substituted hydroxyl group or an optionally substituted amino group, and ring A′ is a benzene ring which may have further substituent in addition to a group represented by the following formula
• wherein, each symbol has the same meaning as described above, or a salt thereof.

A method of preventing, treating, or pain-relieving acute cerebrovascular disorders, spinal damage, head injury, multiple sclerosis, glaucoma, depression, vomit, arthritis or asthma, comprising administering an effective amount of a compound represented by Formula (I0)

• wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R0 is an acylamino group, ring A0 is a benzene ring which may further have a substituent in addition to R0, and ring B is an optionally substituted 5-membered heterocycle, or a salt thereof or a prodrug thereof to a subject in need of such treatment.

A method of preventing or treating memory disorders, psychiatric diseases, obesity, mental diseases, anxiety, depression, drug-dependency, Alzheimer's dementia or Parkinson's disease, or a method of aiding smoking cessation, which is characterized by administering an

• effective amount of a compound represented by Formula (Io)
• wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R0 is an acylamino group, ring A0 is a benzene ring which may further have a substituent in addition to R0, and ring B is an optionally substituted 5-membered heterocycle, or a salt thereof or a prodrug thereof to a subject in need of such treatment.

A method of preventing or treating multiple sclerosis, neurodegenerative diseases, irritable bowel syndrome, Crohn's Disease, reflux oesophagitis, COPD, psoriasis, autoimmune diseases, graft rejection, allergic diseases, neuropathic pain, hepatitis virus or hypertension, or a method of regulating immunity, which is characterized by administering an effective amount of a compound represented by Formula (I0)

• wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R0 is an acylamino group, ring A0 is a benzene ring which may further have a substituent in addition to R0, and ring B is an optionally substituted 5-membered heterocycle, or a salt thereof or a prodrug thereof to a subject in need of such treatment.

Use of a compound represented by Formula (I0)

• wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R0 is an acylamino group, ring A0 is a benzene ring which may further have a substituent in addition to R0, and ring B is an optionally substituted 5-membered heterocycle, or a salt thereof or a prodrug thereof, for manufacturing an agent of preventing or treating acute cerebrovascular disorders, spinal damage, head injury, multiple sclerosis, glaucoma, depression, vomit, arthritis or asthma;
• or for manufacturing an analgesic agent.

Use of a compound represented by Formula (I0)

• wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R0 is an acylamino group, ring A0 is a benzene ring which may further have a substituent in addition to R0, and ring B is an optionally substituted 5-membered heterocycle, or a salt thereof or a prodrug thereof, for manufacturing an agent of preventing or treating memory disorders, psychiatric diseases, obesity, mental diseases, anxiety, depression, drug-dependency, Alzheimer's dementia or Parkinson's disease, or an aid for smoking cessation.

Use of a compound represented by Formula (I0)

• wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R0 is an acylamino group, ring A0 is a benzene ring which may further have a substituent in addition to R0, and ring B is an optionally substituted 5-membered heterocycle, or a salt thereof or a prodrug thereof, for manufacturing an agent of preventing or treating multiple sclerosis, neurodegenerative diseases, irritable bowel syndrome, Crohn's Disease, reflux oesophagitis, COPD, psoriasis, autoimmune diseases, graft rejection, allergic diseases, neuropathic pain, hepatitis virus or hypertension, or an agent of regulating immunity.

(+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide or a salt thereof.

N-(7-acetyl-3-(4-isopropylphenyl)-4,6-dimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide or a salt thereof.

N-(3-(4-isopropylphenyl)-7-methoxy-4,6-dimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide or a salt thereof.

(+)-N-((3R)-7-acetyl-3-(4-isopropylphenyl)-4,6-dimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide or a salt thereof.

(+)-N-(tert-butyl)-N′-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)urea or a salt thereof.

N-(3-(4-isopropylphenyl)-4,6-dimethyl-7-phenyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide or a salt thereof.

N-(7-(3-dimethylaminophenyl)-3-(4-isopropylphenyl)-4,6-dimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide or a salt thereof.

N-(3-hydroxypropyl)-N′-(3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)urea or a salt thereof.

N-((4-isopropyl-3-(2-methoxyethoxy)phenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide or a salt thereof.

N-(7-(4-isopropylbenzyl)-3,4,6-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide or a salt thereof.

N-(3-(4-tert-butylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide or a salt thereof.

N-(3-(4-isopropylphenyl)-4,6,7-trimethyl-3H-spiro(1-benzofuran-2,1′-cyclopentan)-5-yl)-3,3-dimethylbutanamide or a salt thereof.

N-(3-(4-isopropylphenyl)-4,6-dimethyl-7-propyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide or a salt thereof.

N-(7-(6-fluoropyridin-3-yl)-3-(4-isopropylphenyl)-4,6-dimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide or a salt thereof.

N-(7-(3-furyl)-3-(4-isopropylphenyl)-4,6-dimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide or a salt thereof.

N-(7-hydroxy-3-(4-isopropylphenyl)-4,6-dimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide or a salt thereof.

N-(7-ethoxy-3-(4-isopropylphenyl)-4,6-dimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide or a salt thereof.